Tumor Molecular Analysis

Overview

About this study

The purpose of this study is to develop preclinical models that include cell lines and patient derived xenografts (PDX) that include molecular characterization and testing novel therapies in these preclinical models. Molecular characterization may include short tandem DNA repeat; STR) and oncogenic/tumor suppressor gene mutation analyses to assure that the derived models have not been cross contaminated during the development process with other ongoing lines. Tissue microarray and immunohistochemical (IHC) analysis will also be performed on cell lines, PDX and patient tissues to identify potential molecular targets for therapy.

For patients who consented, patient clinical therapy response data may be correlated with preclinical response data in cell lines and PDX models. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients must be 18 years of age or older. 
  • Patients must have signed an informed consent form

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Aaron Mansfield, M.D.

Open for enrollment

Contact information:

Aaron Mansfield M.D.

(507) 293-0569

Mansfield.Aaron@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Nathalie Meurice, Ph.D.

Open for enrollment

Contact information:

Alan Bryce M.D.

(480) 301-4800

Bryce.Alan@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

John Copland, Ph.D.

Open for enrollment

Contact information:

Mauricia Buchanan R.N.

Buchanan.Mauricia@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20492435

Mayo Clinic Footer